Stay updated with breaking news from Ali Chartan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO - EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed
Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) GAITHERSBURG, Md., Dec. 21, 2021 /PRNewswire/ --...
First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX WHO EUL for Nuvaxovid currently under assessment; will be completed
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
Press release content from PR Newswire. The AP news staff was not involved in its creation.